Gefitinib capsules IP
Generic name: Gefndr Product
name: Gefitinib capsules IP
Preparation: tablets
Specification: 250mgx30tablets
Product
Azd-9291 (Gefitinib) is a highly selective EGFR mutant inhibitor. The IC50 of exon 19 deleted EGFR, L858R / T790M EGFR and wild-type EGFR are 12.92 nm, 11.44 nm and 493.8 nm, respectively. The molecular weight is 499.61 and the molecular formula is c28h33n7o2.
Azd-9291 can be used to develop drugs for advanced non-small cell lung cancer and oral drugs for patients with advanced non-small cell lung cancer. At the same time, for patients with advanced lung cancer who take domestic Kemena, gefitinib (Iressa) and erlotinib hydrochloride (trokai), the therapeutic effect is very obvious after drug resistance.
Patients taking Iressa and Kemena usually begin to develop drug resistance in about one year. Some patients can take 3-5 years to develop drug resistance, but this is a small number. Most patients have developed drug resistance in 1-2 years. Although it can be improved by appropriately increasing the dose and replacing erlotinib hydrochloride (trokai), the general time will not last long. Erlotinib hydrochloride (Troika) drug resistance time is far less than Iressa long, generally more than half a year began to produce drug resistance, most patients in half a year to a year drug resistance, very few take erlotinib hydrochloride (Troika) more than a year effect is still obvious patients.
INDAR (INDAR) has launched more than 600 kinds of drugs, including conventional oral tablets, capsules, suspensions, eye drops and injectable biological products. Advanced production line, clean GMP plant and strict quality control have won GMP certification from drug regulatory authorities of many countries, including MHRA (British drug administration) and EU (European Union). Its products are exported to all parts of the world, including the UK, EU Member States and many developing countries.
